Experts Shaji Kumar, Elena Zamagni, and Bruno Paiva discuss novel technologies for risk stratification in smoldering myeloma. They explore AI-driven early intervention and advancements in treating smoldering myeloma, emphasizing patient-focused therapy decisions and effective screening strategies.

Experts Uma Borate, Kelly Bolton, and Eric Padron discuss the early stages of blood disorders, CHIP, and CCUS, emphasizing the importance of multidisciplinary teamwork. They cover topics such as blood cancer risk assessment, diagnostic challenges, bone marrow biopsies, and the connection between clonal hematopoiesis patients and cardiovascular diseases.

Experts Stephen Ansell, Paolo Ghia, and Andrew Rawstron discuss Monoclonal B-cell lymphocytosis (MBL) as a precursor to CLL, exploring biology, classification, and early interception possibilities. They cover MBL progression, genetic similarities with CLL, B-cell receptor as an early marker, and the importance of immune system interactions for early intervention.

Dr. Maria-Victoria Mateos discusses the impact of CAR-T therapy in myeloma, patient selection, and the evolving role of autoSCT. They explore the significance of CAR-T therapy in earlier treatment lines and optimizing outcomes through patient selection and therapeutic sequencing.

Experts in the field discuss the challenges of diagnosing amyloidosis, the significance of cardio-oncology, and the current therapies available. They emphasize the importance of a multidisciplinary team in treating patients and highlight the critical role of early diagnosis and collaboration between specialists for successful management.

Exploring the importance of lymphodepletion in CAR-T therapy, addressing factors contributing to ICAHT, and discussing the cost effectiveness of CAR-T treatment. Insights from experts on personalized dosing, toxicity reduction, and financial implications of these agents.

Renowned experts discuss challenges & advancements in CAR-T therapy for Acute Lymphoblastic Leukemia. Topics include dual targeting of CD19 & CD22, management considerations for patients, outcomes in post-transplant relapse, and strategies for T cell ALL treatment.

Experts discuss the growing role of menin inhibitors in AML treatment, highlighting promising results from clinical trials. They explore the potential of menin inhibitors as standalone or combination therapy, focusing on their efficacy in specific AML mutations and the possibility of bridging patients to stem cell transplants.

Experts discuss challenges and novel approaches in lower- and higher-risk MDS including red blood cell transfusion dependence, failure of EASAs, and potential treatment options. Emphasis on the need for more agents and combinations. They also explore alternative options, clinical trials, and personalized treatment for high-risk MDS. Results of a phase two trial using monoclonal antibody Sabotolomab show improved response and longer progression-free survival.

Thalassemia experts discuss gene therapies, ongoing trials, and precision medicine for thalassemia treatment. Updates on pharmacologic therapy, complications in adult patients, and treatment options for aging patients. Precision therapy and stem cell depletion are also explored.